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Abstract This study aims to stratify prognosis of triple-
negative breast cancer (TNBC) patients using pre-treat-
ment 18F-FDG-PET/CT, alone and with correlation to
immunohistochemistry biomarkers. 200 consecutive TNBC
breast cancer patients treated between 2008 and 2012 were
retrieved. Among the full cohort, 79 patients had pre-
treatment 18F-FDG-PET/CT scans. Immunostaining status
of basal biomarkers (EGFR, CK5/6) and other clinico-
pathological variables were obtained. Three PET image
features were evaluated: maximum uptake values (SUV-
max), mean uptake (SUVmean), and metabolic volume
(SUVvol) defined by SUV[ 2.5. All variables were ana-
lyzed versus disease-free survival (DFS) using univariate
and multivariate Cox analysis, Kaplan-Meier curves, and
log-rank tests. The optimal cutoff points of variables were
estimated using time-dependent survival receiver operating
characteristic (ROC) analysis. All PET features signifi-
cantly correlated with proliferation marker Ki-67 (all
p\ 0.010). SUVmax stratified the prognosis of TNBC
patients with optimal cutoff derived by ROC analysis
(B3.5 vs.[3.5, AUC = 0.654, p = 0.006). SUVmax and
EGFR were significant prognostic factors in univariate and
multivariate Cox analyses. To integrate prognosis of bio-
logical and imaging markers, patients were first stratified
by EGFR into low (B15 %) and high ([15 %) risk groups.
Further, SUVmax was used as a variable to stratify the two
EGFR groups. In the high EGFR group, patients with high
FDG uptake (SUVmax[ 3.5) had worse survival outcome
(median DFS = 7.6 months) than those patients with
low FDG uptake (SUVmax B 3.5, median DFS =
11.6 months). In the low EGFR group, high SUVmax also
indicated worse survival outcome (17.2 months) than low
SUVmax (22.8 months). The risk stratification with inte-
grative EGFR and PET was statistically significant with
log-rank p  0.001. Pre-treatment 18F-FDG-PET/CT
imaging has significant prognostic value for predicting
survival outcome of TNBC patients. Integrated with basal-
biomarker EGFR, PET imaging can further stratify patient
risks in the pre-treatment stage and help select appropriate
treatment strategies for individual patients.
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Abbreviations
TNBC Triple-negative breast cancer
PET Positron emission tomography
CT Computed tomography
18F-FDG 18-fluoro-2-deoxy-D-glucose
SUV Standard uptake value
SUVmax Maximum value of SUV of a defined volume
SUVmean Mean value of SUV of a defined volume
SUVvol Volume of interested segmented by a
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HER2 Human epidermal growth factor receptor 2
EGFR Epidermal growth factor receptor
CK5/6 Cytokeratin 5/6
Introduction
Triple-negative breast cancers (TNBCs) are a heteroge-
neous group of tumors generally characterized by poor
patient survival and lack of targeted therapeutics [1–3].
The majority of TNBCs are aggressive basal-like subtypes
presenting with larger tumors of higher grade, and
increased numbers of involved nodes. A minority of
TNBCs, e.g., luminal androgen receptor, are a less
aggressive subtype associated with better survival outcome
[4–7]. Stratification of TNBC prognosis would be highly
desired since some patients with better prognosis might be
benefit from appropriate targeted treatment [4–6]. Gene
profiling selection would be a direct approach to this need
[7], however, classifying a single cancer into a gene
expression subtype is impracticable in clinical practice
[8–10]. An efficient approach would use immunohisto-
chemistry (IHC) surrogates and other clinical available
information to stratify TNBC patients upfront of treatment.
18-fluoro-2-deoxy-D-glucose positron emission tomog-
raphy/computed tomography (18F-FDG-PET/CT) has been
used at the time of diagnosis of breast cancer to evaluate
tumor staging, especially in the setting of metastasis prior
to surgery or other treatment [12–14]. Recent studies show
that FDG-PET has prognostic value to classify different
breast cancer phenotypes [15]. Basu et al. [16] reported that
tumor uptake value of 18F-PET for TNBC is significantly
different compared to other phenotypes. Groheux et al.
[17–19] have also showed that uptake values significantly
change in TNBC patients who have been treated with
neoadjuvant therapy. However, no PET imaging study to
date has reported on the stratification of prognosis among
TNBC patients. Given the heterogeneity of imaging sig-
natures across the different breast cancer subtypes [15], it is
feasible to use PET imaging to stratify TNBC patients
through association with expression status of prognostic
biomarkers.
This study aims to stratify prognostic TNBC patients
using pre-treatment PET/CT alone and with correlation to
immunohistochemistry biomarkers. We retrospectively
evaluate the relationships among tumor metabolic activities
and clinicopathological factors, and identify the prognostic
value of PET image in predicting patient survival outcome.
An integrative approach of imaging and tissue biomarkers
is proposed to identify global tumor metabolic/biological
status and to stratify individual patient risk. Since both PET
and IHC biomarkers can be clinically available before
starting treatment, the proposed method also provides a




After approval by the institutional review board, informa-
tion was retrospectively collected on 200 consecutive
TNBC patients who had undergone a resection of primary
tumors at our medical center from 2008 to 2012. No con-
sent was needed in the study. All patients were histologi-
cally confirmed as invasive carcinoma, and all patients
received excisional biopsy, radical mastectomy, or modi-
fied radical mastectomy with lymph node dissection as
primary treatment. 167 of these patients were treated with
chemotherapy and/or radiotherapy. All tissue samples were
examined by immunohistochemistry, and all samples with
negative status of ER, PR, and HER2/neu were included.
Among the full cohort, 79 patients had pre-treatment
PET/CT scans. To reduce the bias introduced by the lim-
ited numbers of patients with PET/CT images, the prog-
nostic values of clinicopathological variables were
examined in both full cohort of patients (n = 200) and
subgroup patients with PET/CT images (n = 79). The
resultant significant variables were used to correlate with
the image features of PET images.
PET/CT imaging and image analysis
Patients fasted for 6 h prior to PET/CT imaging, and blood
glucose level had to be less than 7 mmol/l. The dose of
intravenous 18F-FDG was given based on body mass,
using a reference of 370 MBq for 65 kg and not exceeding
555 MBq. After administration of 18F-FDG, patients res-
ted in a quiet room for 60 min. CT and PET images were
then acquired in a Gemini PET/CT scanner (germanium
oxyorthosilicate-based PET ? 16-slice CT; Philips
Healthcare, Bothell, Washington). The patients were
scanned from the level of the mid-thigh to the base of the
skull with their arms raised. CT imaging was performed
with a 16-slice multi-detector scanner using the following
parameters: 0.5 s per rotation, 100 mA tube current,
120 kVp tube voltage, 5 mm slice thickness, and 4.25 mm
slice interval. PET images were acquired using 4-mm slice
thickness and 5 min per bed position for the area of interest
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and 3 min per bed position for all other areas. Acquired
images were iteratively reconstructed with CT-based
attenuation correction.
PET/CT images were analyzed with VelocityAI 3.0
(Varian Medical Systems, Palo Alto, CA). 18-F FDG
uptake was measured by the standard uptake value (SUV),
which represents the radioactivity of tissue for given time,
mass, and initial tracer injection. The maximum uptake
value (SUVmax) was used to characterize the tumor
metabolic activities for a given region of interest, which
was verified by biopsy/surgical location obtained from
clinical pathology reports. SUV[ 2.5 was used to define
the tumor-associated metabolic volume, SUVvol [13, 20].
The mean uptake value within the metabolic volume is
defined as SUVmean.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were
selected to include representative sections of carcinoma and
adjacent normal breast tissue. All IHC stainswere performed
using a Polymer and/or SA-HRP Detection System. Estro-
gen (ER) and progesterone receptor (PR) status, Ki-67, P53,
andHER2/neu labeling indexwere determinedwith the SP1,
1E2, K-2, DO7, and 4B5 antibodies (Ventana Medical
Systems, Tucson, AZ, USA), respectively. ER, PR, Ki-67,
and P53 immunoexpressions were evaluated as the per-
centage of cells exhibiting definite nuclear staining. The
threshold for the definition of TNBC was a lack (\1 %
positivity) of any ER and PR immunoreactivity and a score
of 0 or 1? for HER2/neu immunoexpression and absence of
amplification by fluorescent in situ hybridization (FISH).
The PathVysion HER2 DNA probe kits (Abbott Molecular,
Chicago, IL, USA) were used to specify the ratio of HER2/
neu over the chromosome 17. A ratio less than 1.8 is negative
for HER2 amplification and a ratio greater than 2.2 is posi-
tive for amplification, whereas a ratio of 1.8 to 2.2 is con-
sidered as equivocal for amplification. Immunostaining for
CK 5/6 and EGFR was performed using monoclonal anti-
bodies D5/16 B4 for CK5/6 (Dako, Glostrup, Denmark) and
2-18C9 for EGFR (Dako, Glostrup, Denmark). Results were
recorded as the percentage of invasive carcinoma cells
showing cytoplasmic and/or cytoplasmic membrane
immunoreactivity for the corresponding antigen and the
intensity of staining. The basal-like phenotype is defined as
triple negative (ER, PR, and HER2 negative) and EGFR or
CK5/6 positive [21].
Statistical analyses
Patient’s disease-free survival (DFS) was defined from the
date of the primary treatment to the date of first local
recurrence or distant metastasis or death [22]. Statistical
analysis was performed using R software 3.1.1 (The R
foundation for statistical computing, Vienna, Austria) and
SPSS 17.0 statistical software (SPSS Inc, Chicago, IL,
USA).
Prognostic values for DFS were examined along with
clinicopathological factors such as age, tumor size, modi-
fied Bloom-Richardson (MBR) score, nuclear grade, tubule
formation, mitosis, pathologic tumor stage (TNM-pT),
lymph node stage (pN), metastasis (pM), ER, PR, HER2/
neu, P53, Ki-67, CK5/6, and EGFR. The association of
these variables with survival was analyzed using univariate
and multivariate Cox-proportional hazard regression anal-
ysis. The independence of individual clinicopathological
variables was examined by correlation. The cutoff values
of biomarkers were estimated by the time-dependent sur-
vival ROC curves (survival ROC library in R), which were
able to identify the threshold value by taking into account
the number of months until censoring or recurrence from
disease [23–26]. The resultant cutoff values were further
examined by the Kaplan-Meier curves and log-rank tests
[27, 28].
For the patients with pre-treatment PET/CT images,
prognostic values of image features, SUVmax, SUV-
mean, and SUVvol were evaluated. The significant
clinicopathological factors identified in the full cohort
data were also re-evaluated in the imaging subgroup.
The statistical difference between subgroup patients with
and without PET/CT images was evaluated by Wilcoxon
rank sum tests. A p value less than 0.05 was considered
significant.
Results
Patient and tumor characteristics are summarized in
Table 1. All patients in the full cohort were women with a
median age of 57 years (range, 28–92 years) and a median
disease-free survival of 11.5 months. No significant dif-
ference was observed between patients with and without
PET/CT images. The imaging subgroup had a median age
of 57 years (range, 28–88 years) and a median disease-free
survival of 11.4 months. 70 % patients were CK5/6 posi-
tive, and 91 % patients were EGFR positive. A total of 73
(92 %) patients were identified as having basal-like TNBC
(any EGFR and/or CK5/6 positivity). 67 patients were
treated with chemotherapy and/or radiotherapy, and 12
patients were treated with neither chemotherapy nor
radiotherapy. Figure 1 shows two TNBC cases of pre-
treatment PET/CT images with the different SUVmax and
prognosis: patient 1, diagnosed with low SUVmax (=1.5)
and low expressions of basal marker (EGFR = 10 %,
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CK5/6 = 10 %), is still event free after 24 months; patient
2, diagnosed with high SUVmax (=19.7) and high
expressions of EGFR (=70 %) and CK5/6 (=95 %), had
lung metastasis after 21 months event free.
Prognosis of PET Image features
All image features (SUVmax, SUVmean, SUVvol) signif-
icantly correlated with proliferation marker Ki-67
Table 1 Patient characteristics
Variables TNBC patients Subgroup TNBC patients
with pre-treatment PET/CT
Number of patients Percentage % Number of patients Percentage %
All patients 200 100 79 100
Age
B50 71 35 31 39
[50 129 65 48 61
Size
B20 mm 99 52 37 47
[20 mm 92 48 42 53
MBR
\3 24 12 10 13
=3 171 88 69 87
TNM, pT stage
\3 166 90 67 87
C3 18 10 10 13
TNM, pN stage
\1 116 67 40 57
C1 57 32 31 43
TNM, pM stage
\1 192 96 76 79
C1 8 4 3 21
Ki-67
B50 % 96 48 37 47
[50 % 104 52 42 53
P53
B50 % 67 45 23 37
[50 % 82 55 39 63
EGFR
=0 % 17 9 7 9
0–15 % 40 20 20 26
[15 % 141 71 50 65
CK5/6
=0 % 51 25 24 30
0–50 % 110 55 36 46
[50 % 39 20 19 24
SUVmax
B3.5 – – 26 29
[3.5 – – 53 71
SUVmean
B2.9 – – 29 25
[2.9 – – 50 75
SUVvol
B10 ml – – 54 60
[10 ml – – 25 39
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(p\ 0.010) and significantly correlated with each other (all
with p\ 0.001). Additionally, SUVmax significantly cor-
related with tumor MBR grade (p = 0.034) and tumor
mitotic index (p = 0.019), whereas SUVmean also sig-
nificantly correlated with tumor MBR grade (p = 0.025),
mitotic index (p = 0.032), and CK5/6 (p = 0.031). SUV-
vol significantly correlated with tumor size (p  0.001),
pathological T stage (p = 0.023).
The prognostic values of image features were
examined by univariate Cox analysis, as shown in
Table 2. Maximum FDG uptake (SUVmax) was sig-
nificant in both continuous (p = 0.021) and discrete
status (B3.5 vs.[3.5) with p = 0.006. The cutoff value
of SUVmax was estimated using time-dependent sur-
vival ROC analysis. As a result, cutoff 3.5 maximized
both sensitivity and specificity of SUVmax for the
disease-free survival with AUC = 0.654. Figure 2b
shows the ROC of SUVmax, where the cutoff point is
marked by the red circle. The resultant cutoff percentile
was verified by examining the prognostic value of
SUVmax using log-rank test (p = 0.002) and Cox
regression analysis (p = 0.006). As shown in Fig. 2a,
patients were stratified into two risk groups with
SUVmax (B3.5 vs. [3.5), and the patients in high
SUVmax groups had worse survival outcome.
Mean FDG uptake (SUVmean) was also significant in
stratifying patient risks with optimal cutoff 2.9. The
prognostic difference between two patient risk groups
was illustrated by Kaplan-Meier curves (log-rank
p = 0.005) shown in Fig. 2c. Metabolic uptake volume
(SUVvol) has the similar results shown in Fig. 2d, where
patients with large metabolic volume had worse outcome
than those with small volume (B10 ml vs. 10 ml,
p = 0.001). Due to the strong correlation (p  0.001)
between SUVvol and pathological volume derived by the
tumor size, we compared the difference between these
two volumes using Wilcoxon rank sum test. The results
show that PET-defined tumor volume was not signifi-
cantly different from the pathology-derived tumor vol-
ume (p[ 0.10). This suggests that PET-defined volume
can be used to estimate tumor volume prior to surgery or
other treatment.
Prognostic value of basal biomarkers
Basal biomarkers EGFR and CK5/6 were evaluated by
univariate Cox analysis in both continuous and discrete
status. The optimal cutoff values were estimated using
time-dependent survival ROC analysis. As a result, an
EGFR cutoff of 15 % maximized both sensitivity and
specificity for the outcome with AUC = 0.788, and
while for CK5/6, 50 % is the optimal cutoff point with
AUC = 0.611. As shown in Table 2, EGFR and CK5/6
were both significant in univariate Cox analysis with
p = 0.001 and 0.011, respectively. The stratification of
patient risks is illustrated by Kaplan-Meier curves
(Fig. 3), with log-ranks p = 0.0008 for EGFR and 0.011
for CK5/6, respectively. To remove the bias due to
sample size, the same tests were also conducted in full
cohort patients (n = 200), and produced the same results
(p = 0.004 for EGFR, p = 0.018 for CK5/6) shown in
Table 2.
Integrating prognosis of PET imaging and basal
biomarkers
Multivariate Cox analysis in Table 2 identifies that SUV-
max and EGFR were significant prognostic factors for
disease-free survival (p = 0.031, and 0.004, respectively).
To integrate prognosis of biological and imaging markers,
patients were first stratified by EGFR into low (B15 %)
and high ([15 %) risk groups. Further, SUVmax was used
(a)
(b)
Fig. 1 Two TNBC cases of pre-treatment PET/CT images with the
different SUVmax and prognosis. PET images were fused with CT
images, and the locations of tumor were pointed by yellow arrows.
a SUVmax = 1.5 for a 77-yr-old patient with EGFR = 10 %, CK5/
6 = 10 %, Ki-67 = 39 %, who was undergone lumpectomy and is
still event free after 24 months. b SUVmax = 19.7 for a 75-yr-old
patient with EGFR = 70 %, CK5/6 = 95 %, Ki-67 = 57 %, SUV-
mean = 7.5, SUVvol = 52.1 cc, who was undergone lumpectomy,
and had lung metastasis after 21 months event free
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HR (95 % CI) p value HR (95 % CI) p value HR (95 % CI) p value
TNM, pT stage,\3 versus C3 2.724 (1.198–6.193) 0.017 1.786 (0.603–5.294) 0.295 2.337(0.428–7.384) 0.148
TNM, pN stage,\1 versus C1 2.001 (1.010–3.696) 0.047 1.999(0.774–5.163) 0.153 – –
TNM, pM stage, =0 versus[0 3.503 (1.387–8.848) 0.008 5.751 (1.292–25.61) 0.022 – –
Ki-67 % continuous 1.009 (0.996–1.022) 0.156 1.012 (0.992–1.032) 0.248 – –
B50 % versus[50 % 1.689 (0.592–2.941) 0.064 1.710 (0.756–3.866) 0.197 – –
EGFR % continuous 1.010 (1.001–1.019) 0.039 1.039 (1.020–1.057) 0.001 – –
B15 % versus[15 % 3.612 (1.418–7.253) 0.004 12.05 (2.793–52.01) <0.001 9.109 (1.997–41.55) 0.004
CK5/6 % continuous 1.007 (0.997–1.017) 0.101 1.008 (0.992–1.022) 0.055 – –
B50 % versus[50 % 2.201 (1.142–4.242) 0.018 2.959 (1.282–6.829) 0.011 1.471 (0.598–3.614) 0.401
SUVmax continuous – – 1.053 (1.008–1.101) 0.021 – –
B3.5 versus[3.5 – – 5.490 (1.629–18.51) 0.006 3.883(1.13–13.32) 0.031
SUVmean continuous – – 1.279 (1.109–1.474) <0.001 – –
B2.9 versus[2.9 – – 3.677 (1.488–9.087) 0.005 – –
SUVvol continuous – – 1.013 (1.000–1.030) 0.012 – –
B10 ml versus[10 ml – – 3.919 (1.737–8.843) 0.001 – –
Log-rank p = 0.002  AUC=0.654
SUVmax
(c) (d) 
Log-rank p < 0.001  Log-rank p < 0.001  
(b) (a) 
Fig. 2 Kaplan-Meier curves of disease-free survival of PET image
features for TNBC patients with pre-treatment PET/CT, a SUVmax at
cutoff level 3.5 with log-rank p = 0.002, b SUVmax cutoff value (red
circle) is determined by time-dependent survival ROC curve with AUC
= 0.654, c SUVmean at cutoff level 2.9 with log-rank p\ 0.001, and
d SUVvol at cutoff level 10 ml with log-rank p\ 0.001
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as a variable to stratify the two EGFR groups. In the high
EGFR group, patients with high FDG uptake (SUV-
max[ 3.5) had worse survival outcome (median
DFS = 7.6 months) than those patients with low FDG
uptake (SUVmax B 3.5, median DFS = 11.6 months). In
the low EGFR group, high SUVmax also indicated worse
survival outcome (17.2 months) than low SUVmax
(22.8 months). Figure 4 shows that the risk stratification
with integrative EGFR and PET was statistically significant
with log-rank p  0.001. The results of patient risk groups
stratified by SUVmax and EGFR are listed in Table 3. The
majority of TNBC patients (47 %) were in group 4 with
high SUVmax and high EGFR expression. Compared to
low-risk groups, group 4 has the shortest median DFS
(7.6 months), highest median SUVmax (11.3), SUVmean
(5.2), SUVvol (10.9 ml), EGFR (60 %), CK5/6 (20 %),
and Ki-67 (60 %). Contrarily, the low-risk group 1 has all
favorable characteristics: long DFS (22.8 months), and low
expression EGFR (5 %), and SUVmax (2.0).
Discussion
TNBC is a highly diversity group of cancers with character
of the absence of expression of ER, PR, and HER2 [1, 2].
Recent gene expression microarray studies have revealed at
least six subtypes, with luminal androgen receptor or
molecular apocrine cancers forming a distinct group within
triple-negative disease [3, 4]. This finding suggests that the
prognosis of TNBC subtypes would be different due to
diversity of genomic expression. However, the selection of
gene expression subtypes for a single cancer is challenging
in the clinics [8]. Recent clinical trials on EGFR suggest
that it is unlikely that a targeted therapy will have sub-
stantial effective activity in unselected TNBCs [29, 30]. An
efficient approach would use biomarker or other methods
to screen for the potentially sensitive subset of patients [4,
11]. Considering cost and efficiency, it is also highly
desirable for the screening to be completed during regular
clinical procedures.
IHC and PET/CT are commonly performed before pri-
mary treatment starts. Both methods have their advantages
and disadvantages in stratification of breast cancer. IHC
biomarkers CK5/6 and EGFR have been used to identify
basal-like breast cancer in clinical routine. Expression of
EGFR and/or CK5/6 has been used to predict the basal
phenotype associated with poor survival [22]. Recent
studies [31–33] suggested that the overexpression level of
basal markers may affect the stratification of TNBC
patients. Viale et al. [31] showed that immunoreactivity of
EGFR may have different prognostic values at different
Log-rank p = 0.0008  
Log-rank p = 0.011  
(a)
(b)
Fig. 3 Kaplan-Meier curves of disease-free survival of basal
biomarkers for TNBC patients with pre-treatment PET/CT, a EGFR
at cutoff level 15 % with log-rank p = 0.0008, and b CK5/6 at cutoff
level 50 % with log-rank p = 0.011
Log-rank p< 0.0001 
Fig. 4 Kaplan-Meier curves of disease-free survival of risk groups
for TNBC patients with pre-treatment PET/CT. The patients were
classified into four risk groups: group 1 (EGFR B 15, SUV-
max B 3.5, n = 12), group 2 (EGFR B 15, SUVmax > 3.5,
n = 15), group 3 (EGFR > 15, SUVmax B 3.5, n = 13), and group
4 (EGFR > 15, SUVmax > 3.5, n = 37), with log-rank p\ 0.0001
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123
cutoff points, and low expression of basal biomarkers may
not necessarily lead to poor survival. Zhang et al. [32]
reported that EGFR had more significant prognostic value
than CK5/6 in the study of 136 TNBC patients. Thike et al.
[33] showed that basal cytokeratins had significant prog-
nostic values, whereas EGFR did not in their patient
cohort. These suggest that a single biomarker only indi-
cates a specific signaling pathway and thus may not be
reliable to stratify TNBC patients. It is desirable to exploit
a statistical model to integrate information from multiple
biomarkers [33, 34]. In addition, because examined tissue
usually is obtained from a single location, it may not rep-
resent the heterogeneity of a tumor.
18F-FDG-PET/CT has been used in initial staging and
stratification of the phenotypes of breast cancer. Specif-
ically, PET/CT is used to identify occult distant metas-
tases and involvement of extra-axillary lymph node,
which serve as critical indices in initial staging of breast
cancer [14, 35]. A study on a cohort of 142 patients [15]
showed that PET/CT provided stronger prognostic strat-
ification in the primary staging of large breast cancer
than conventional imaging (such as mammogram, breast
ultrasound, bone scan, X-rays, and/or CT). Although
PET imaging is able to provide global metabolic uptake
related to tumorous transformation (e.g., metabolism and
proliferation), the relationship between tumor hetero-
geneity and image features is still ambiguous. Several
efforts [17, 18, 36, 37] have been made to correlate
metabolic uptakes with immunoexpression status of tis-
sue biomarkers. Osborne et al. [36] showed that meta-
bolic activities of ER-negative tumors were significantly
higher than those of ER-positive tumors. Aogi et al. [37]
reported that the maximum metabolic uptake predicted
survival outcome for patients with the luminal-type
breast cancer. Recent study [15] also suggested that FDG
uptake of TNBC tumor typically had higher metabolic
activities than those of other phenotype breast cancers,
and it could be potentially used to predict the outcome
of neoadjuvant chemotherapy [17, 18]. To the best of our
knowledge, no PET imaging study has been reported on
the stratification of prognosis among TNBC patients. Our
method, integration of basal biomarkers and PET pro-
vides a new avenue to identify TNBC patients who
potential have relative good prognosis and may be
spared from overtreatment and those who may need
targeted therapy.
Our results indicate that basal marker EGFR was a
significant biomarker for the large patient cohort (n = 200)
and for a smaller subgroup (n = 79). Not all basal marker
positive breast cancer was necessarily associated with poor
prognosis, and the patients with low expression (e.g.
EGFR\ 15 %) had better survival outcome than those
with EGFR[ 15 %. Similarly, pre-treatment PET also had
significant prognostic value to identify low- and high-risk
patients. The integration of these two prognostic markers
further stratified TNBC patients into four subgroups. The
patients with high EGFR expression and high FDG uptake
had much worse survival outcome than those patients with
low EGFR expression and low FDG uptake. The results
also suggest that non-EGFR pathways play critical roles in
those EGFR positive cases. This might be one of the rea-
sons for the failure of EGFR clinical trials [29, 30]. Since
both biomarkers can be obtained before treatment, these
low-risk patients may be selected as candidates for further
screening with targetable genes. Our prognostic analysis
would help clinicians identify low- and high-risk patients
early, so they could then select appropriate treatment
strategies for the individual TNBC patients. Further study
or analysis may help determine whether study of
EGFR ? PET-guided neoadjuvant therapy warrants a full-
scale clinical trial for TNBC patients.
Conclusions
This work indicates that pre-treatment 18F-FDG-PET/CT
imaging has significant prognostic value for predicting sur-
vival outcome of TNBC patients. Integrated with prognostic
basal biomarkers, especially EGFR, PET imaging can fur-
ther stratify TNBC patients into different risk groups. Given
the limited sample size here, new clinical studies are needed
to assess the specificity and sensitivity of PET imaging in
identification of non-basal-like TNBC defined by expression
gene profiling analysis. Further prospective validation will
help define prognostic and predictive value of the PET
imaging as a pre-treatment screening approach to identify
Table 3 TNBC patient risk groups stratified by EGFR and SUVmax (with the median values of variables)










1 (-, -) 12 22.8 5.0 2.0 0.6 0.3 1.8 4.5 34.5
2 (-, ?) 15 17.2 5.0 8.9 4.3 7.2 2.0 5.0 67.0
3 (?, -) 13 11.6 50.0 2.7 2.6 0.9 1.8 5.0 35.0
4 (?, ?) 37 7.6 60.0 11.3 5.2 10.9 2.0 20.0 60.0
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patients with sensitive targetable genes for clinical trials, and
also help identify patients at higher risk who may benefit
from aggressive treatment strategies.
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